Otros idiomas Q BioMed Inc.

Acciones

QBIO

US74736N1054

Mercado cerrado - OTC Markets Otros sitios de cotización 15:46:06 10/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,000001 ^USD	-99,83 %		0,00 %	-50,00 %

2023	Q BioMed Inc. Resultados del primer trimestre finalizado el 28 de febrero de 2023	CI
2023	Q BioMed Inc. presenta los resultados del ejercicio cerrado el 30 de noviembre de 2022	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Q BioMed Inc. Provides Update to Shareholders	23/06/23
Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	16/06/23
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	26/05/23
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe	17/04/23
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe	14/04/23
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office	13/02/23
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office	10/02/23
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office	10/02/23
Q BIOMED INC. : Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	18/11/22
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	03/11/22
Q BioMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	03/11/22
Q BIOMED PROVIDES SHAREHOLDER UPDATE	11/10/22
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER	27/09/22
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker	27/09/22
Q BioMed Inc. Provides Update to Shareholders	29/07/22
Q BioMed Inc. Reports Second Quarter Revenues in 2022	29/07/22
Q BioMed : Quarterly Report for Quarter Ending May 31, 2022 (Form 10-Q)	28/07/22
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	28/07/22
Q BioMed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	28/07/22
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer	26/07/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Q BioMed Inc.

Acciones

QBIO

US74736N1054

Otros idiomas

Filtros